top of page

Houston Oncology Summit: Talking KRAS & pan-RAS inhibition with MD Anderson’s Ferdinandos Skoulidis

  • blonca9
  • Sep 21, 2023
  • 1 min read

Ferdinandos Skoulidis describes improvements being made to G12C inhibitors and why he believes the theoretical potential for pan-RAS inhibitors is substantial.



Brought to you by:


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTVHQ

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Genezen_Logo_RGB.png

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page